The Vaccine Partnering Terms and Agreements report provides
comprehensive understanding and unprecedented access to the vaccine
partnering deals and agreements entered into by the worlds leading
healthcare companies.
- Trends in vaccine and adjuvant partnering deals
- Deal terms analysis
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for vaccines
The report provides a detailed understanding and analysis of how
and why companies enter vaccine partnering deals. The majority of deals
are discovery or development stage whereby the licensee obtains a right
or an option right to license the licensors vaccine technology. These
deals tend to be multicomponent, starting with collaborative R&D,
and commercialization of outcomes. The report also includes adjuvant
deals and alliances.
Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
do not.
- To Read The Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/19812
This report contains over 1,500 links to online copies of actual
vaccine deals and contract documents as submitted to the Securities
Exchange Commission by companies and their partners. Contract documents
provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have
a significant impact on each party’s ability to derive value from the
deal.
The initial chapters of this report provide an orientation of
vaccine dealmaking and business activities. Chapter 1 provides an
introduction to the report, whilst chapter 2 provides an overview of the
trends in vaccine dealmaking since 2007, including details of average
headline, upfront, milestone and royalty terms.
- For All Latest Reports Visit: http://www.marketresearchreports.biz/latest
Chapter 3 provides a review of the leading vaccine deals since
2007. Deals are listed by headline value, signed by bigpharma, most
active bigpharma, and most active of all biopharma companies. Where the
deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma
companies with a brief summary followed by a comprehensive listing of
vaccine deals as well as contract documents available in the public
domain. Where available, each deal title links via Weblink to an online
version of the actual contract document, providing easy access to each
contract document on demand.
Chapter 5 provides a comprehensive and detailed review of vaccine
partnering deals signed and announced since 2007, where a contract
document is available in the public domain. The chapter is organized by
company A-Z, stage of development at signing, deal type (collaborative
R&D, co-promotion, licensing etc), and specific therapy focus. Each
deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each
contract document on demand.
- To Browse All Reports visit:http://www.marketresearchreports.biz/
The report also includes numerous tables and figures that
illustrate the trends and activities in vaccine partnering and
dealmaking since 2007.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development
and commercialization of vaccine technologies and products.
Vaccine Partnering Terms and Agreements is intended to provide the
reader with an in-depth understanding and access to vaccine trends and
structure of deals entered into by leading companies worldwide.
Vaccine Partnering Terms and Agreements includes:
- Trends in vaccine dealmaking in the biopharma industry since 2007
- Analysis of vaccine deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life vaccine deals
- Access to over 1,500 vaccine deal documents
- The leading vaccine deals by value since 2007
- Most active vaccine dealmakers since 2007
- The leading vaccine partnering resources
In Vaccine Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via weblink to an online version of the deal
record and where available, the contract document, providing easy access
to each contract document on demand.
The Vaccine Partnering Terms and Agreements report provides
comprehensive access to available deals and contract documents for over
1,500 vaccine deals. Analyzing actual contract agreements allows
assessment of the following:
To Buy The Copy Of This Report visit: http://www.marketresearchreports.biz/analysis/19812
- What are the precise vaccine rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
No comments:
Post a Comment